Osteoporosis | Treatment Algorithms: Claims Data Analysis | US | 2025
Osteoporosis is characterized by low bone mass and microarchitectural deterioration of bone tissue, leading to an increase in bone fragility and susceptibility to fracture. A wide array of drugs are available to treat osteoporosis and are categorized as either antiresorptive or anabolic medication. Oral bisphosphonates, especially alendronate, dominate first-line therapy, and Prolia and HRT are generally prescribed as second-line options. Branded agents such as Amgen’s Evenity and Radius Health’s Tymlos are reserved for high-risk patients. This report offers insight on current prescribing trends in the treatment of osteoporosis, based on U.S. real-world claims data.
Questions answered
- What shares do key therapies and brands garner by line of therapy in newly diagnosed osteoporosis patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed osteoporosis patients?
- How has Evenity been integrated into the treatment algorithm, and what is its source of business?
- What percentage of osteoporosis patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within a year of diagnosis?
- What percentage of osteoporosis patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
- Quantify opportunities at different stages of the treatment algorithm.
Markets covered: United States
Key companies: Eli Lilly, Radius Health, Amgen
Key drugs: Oral bisphosphonates, zoledronate, Prolia, teriparatide, Tymlos, Evenity
Key feature
Dashboard featuring interactive visuals, easy navigation, and expanded analyses
